IBI-323 + bevacizumab + platinum

This is a combination regimen consisting of three agents:\n- **IBI-323** is a bispecific monoclonal antibody that targets both programmed death-ligand 1 (PD-L1) and lymphocyte activation gene 3 (LAG-3). It blocks the PD-1/PD-L1 and LAG-3/MHC-II pathways, aiming to enhance antitumor immune responses by overcoming resistance mechanisms in cancer immunotherapy. Preclinical studies show it can bridge PD-L1+ and LAG-3+ cells, leading to superior immune stimulation compared to parental antibodies[5][6].\n- **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis.\n- **Platinum** refers to platinum-based chemotherapeutic agents such as cisplatin or carboplatin, which cause DNA crosslinking and apoptosis in rapidly dividing tumor cells.\n\nThe combination is being investigated for advanced malignancies, particularly solid tumors. The rationale is that dual checkpoint inhibition with IBI-323 may synergize with antiangiogenic therapy (bevacizumab) and cytotoxic chemotherapy (platinum compounds) for improved efficacy[7].

Other names

anti-LAG-3/PD-L1 bispecific antibody + bevacizumab + platinumIBI323 combination therapyIBI-323 combination therapyIBI 323 combination therapy